The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
Remix Therapeutics officially launched with $81 million in financing, with the funds to be used to support the development of the company’s REMaster technology platform while advancing a pipeline of RNA processing targeted therapeutics.
Kate Cronin, Global CEO of Ogilvy Health, shares her views on a variety of healthcare industry topics in a Q&A with PharmaLive.
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
Researchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.
A study published in the Nov. 2 edition of Cell suggests that pancreatic cancer cells avoid starvation by signaling to nerves, which encourages them to grow into dense tumors and release the nutrients the cells need to survive.
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.
Fujifilm Holdings Corp. said a late-stage study of Avigan showed the antiviral drug reduced recovery times for Covid-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.